argenx SE

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action. This case...

Yahoo Finance · 30/07/2026 · lire l'article ↗

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.

Yahoo Finance · 29/07/2026 · lire l'article ↗

argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply toward restocking commercial pipelines with low-risk, high-conviction clinical assets. At the […]

Yahoo Finance · 29/07/2026 · lire l'article ↗

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which is expected to close soon, subject to customary conditions. The deal will result in a change of control for Forte Biosciences, with all remaining shares acquired after completion of the tender. For existing and potential shareholders, Forte Biosciences, NasdaqCM:FBRX, now sits squarely in deal territory. The stock most...

Yahoo Finance · 29/07/2026 · lire l'article ↗

argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal

argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte’s anti CD122 antibody program FB102. See our latest analysis for argenx. argenx shares have had a strong run, with a 1 year total shareholder return of 54.32% and a 5 year total shareholder return of 202.61%. The 90 day share price return of 18.66% and the recent Forte deal suggest momentum has been building into recent earnings and pipeline...

Yahoo Finance · 28/07/2026 · lire l'article ↗

argenx signs agreement to buy Forte Biosciences for $2.2bn

The transaction is expected to close in the third quarter of 2026.

Yahoo Finance · 28/07/2026 · lire l'article ↗